BRCA1 and breast carcinoma: Recently, it has been demonstrated that a defect in homologous recombination can lead to changes in drug sensitivity profile, rendering the BRCA1 deficient breast cancers sensitive to mitomycin C, cisplatin, etoposide and other drugs that produce double-stranded lesions [33].